期刊文献+

肺癌患者外周血肺组织特异性基因mRNA检测的诊断价值 被引量:1

Diagnostic value of detection of lung-specific X protein gene mRNA in the peripheral blood of patients with lung cancer using real-time RT-PCR assay
下载PDF
导出
摘要 目的:探讨荧光定量RT—PCR法测定外周血肺组织特异性基因(1ung-specific X protein gene,LUNX)mRNA表达对肺癌的诊断价值。方法:荧光定量RT—PCR法检测67例肺癌患者(其中30例手术患者测定术前和术后外周血)、40例良性肺疾病患者、20名健康体检者外周血LUNX mRNA表达,67例肺癌患者同时用放免法测定外周血中CEA、CA125、Cyfra21—1。结果:肺癌患者外周血LUNXmRNA表达阳性率(56.7%)均高于CEA、CA125、Cyfra21—1单项或三者联合检测(分别为16.4%、26.9%、11.9%和32.8%)(P〈0.05~P〈0.005)。荧光定量RT—PCR法测外周血LUNXmRNA表达诊断肺癌的敏感性为56.7%,特异性100%,阳性预测值为100%,阴性预测值为67.4%。结论:荧光定量RT—PCR法测定外周血LUNX mRNA可能成为肺癌基因诊断一项较好的指标。 Objective: To explore the value of lung-specific X protein gene (LUNX) mRNA expression in diagnosis of lung cancer. Methods:Real-time RT-PCR assay was used to detect LUNX mRNA in the peripheral blood of 67 patients with lung cancer,40 patients with benign pulmonary disease and 20 healthy volunteers. The serum levels of CEA, CA125 and Cyfra21-1 of 67 patients with lung cancer were simultaneously measured by radioimmunoassay. Results : The positive rate of LUNX mRNA expression in the peripheral blood of patients with lung cancer was higher than that of each one or combination of CEA, CA125 and Cyfra21-1 (56.7% and 11.9% , 16.4% ,26.9% ,32.8% ,respectively) ( P 〈 0.05 - P 〈 0. 005 ), and the sensitivity, specificity, positive predictive value and negative predictive value of LUNX mRNA were 56.7% , 100% , 100% and 67.4% by real-time RT-PCR assay, respectively. Conclusions: LUNX mRNA in peripheral blood detected by Real-Time RT-PCR assay may be a good gene indicator for diagnosis of lung cancer.
出处 《蚌埠医学院学报》 CAS 2007年第3期274-276,共3页 Journal of Bengbu Medical College
关键词 肺肿瘤 荧光定量RT—PCR 肺组织特异性基因 MRNA 外周血 lung noeplasms real-time RT-PCR lung-specific X protein gene mRNA peripheral blood
  • 相关文献

参考文献7

  • 1Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 2Iwao K,Watanabe T,Fujiwara Y,et al.Isolation of a novel human lung-specific gene,LUNX,a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer[J].Int J Cancer,2001,91 (4):433 -437.
  • 3Mitas M,Hoover L,Silvestri G,et al.Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood[corrected][J].J Mol Diagn,2003,5 (4):237-242.
  • 4陆舜.非小细胞肺癌综合治疗新进展[J].中国肺癌杂志,2005,8(1):74-76. 被引量:21
  • 5Ghossein RA,Bhattacharya S,Rosai J.Molecular detection of micrometastases and circulating tumor cells in solid tumors[J].Clin Cancer Res,1999,5(8):1 950-1 960.
  • 6Pantel K,Izbicki J,Passlick B,et al.Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases[J].Lancet,1996,347 (9 002):649-653.
  • 7Baker MK,Mikhitarian K,Osta W,et al.Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcriptionpolymerase chain reaction and a novel porous barrier density gradient centrifugation technology[J].Clin Cancer Res,2003,9(13):4 865 -4 871.

二级参考文献9

  • 1Kim TY, Yang SH, Lee SH, et al. A phase Ⅲ randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol,2002,25(3): 238-243.
  • 2Morris DE, Rosenman JG, Halle JS, et al.Induction chemotherapy followed by doseescalated thoracic 3 dimensional conformal radiation therapy to 90 Gy with concurrent chemotherapy in stage Ⅲ A/B non-small cell lung cancer: a phase Ⅰ radiation dose escalation trial. Int J Radiat Oncol Biol Phys,2003,57(2 Suppl): S138-S139.
  • 3Chemotherapy in non small cell lung cancer:a meta-analysis using updated data on indi vidual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ,1995,311(7010) : 899-909.
  • 4Le Chevalier T, for the IALT Investigators.Results of the Randomized International Ad juvant Lung Cancer Trial (IALT): cisplatinbased chemotherapy (CT) vs no CT in 1867patients (pts) with resected non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol,2003,23(abstr. 6).
  • 5PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer (Cochrane Review) [J/CD].The Cochrane Library, Issue 1,2001. Oxford: Update Software.
  • 6Kato H, Tsuboi M, Ohta M, et al. A randomized phase Ⅲ trial of adjuvant chemotherapy with UFT for completely resected pathological stage Ⅰ (T1N0M0, T2N0M0)adenocarcinoma of the lung. Proc Am Soc Clin Oncol, 2003,23 (abstr. 2498).
  • 7Albain KS, Scott CB, Rush VR, et al.Phase Ⅲ comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage Ⅲ a (Pn2) non-small-cell lung cancer(NSCLC): Initial results from intergroup trial 0139(RTOG93-09). Proc Am Soc Clin Oncol,2003,22: 621(abstr. 2497).
  • 8周清华, Liu LX, Li L, et al. A randomized clinical trial of preoperative neoadjuvant chemotherapy followed by surgery in the treatment of stage Ⅲ non-small cell lung cancer. Lung Cancer, 2003,41 (S2) :S45-S46.
  • 9廖美琳,周允中,丁嘉安,倪国兴,赵家美,陈文虎,韩宝惠,沈洁,白皓,陈智伟,纪灏,王慧敏,周箴.围手术期化疗在非小细胞肺癌中的应用探讨[J].中华医学杂志,2003,83(11):962-966. 被引量:25

共引文献20

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部